Diego J. Maselli, AAAAI 2021: Outcomes of the CAPTAIN Study in Subgroups Defined by BMI
We were delighted to talk to Diego Maselli (University of Texas Health Science Center at San Antonio, TX, US) around the effects of Body Mass Index (BMI) on response to the triple therapy of fluticasone furoate, umeclidinium, and vilanterol in patients with inadequately controlled asthma (Clinical Trial Identifier: NCT02924688).
The abstract ‘CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting b2-agonists (ICS/ LABA).’ (ABSTRACT NUMBER: 176) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What has the CAPTAIN trial taught us about the clinical utility of the single inhaler triple therapy of fluticasone furoate, umeclidinium, and vilanterol in the treatment of patients with uncontrolled asthma? (0:23)
- What were the results of your analysis of the CAPTAIN study data in subgroups defined by BMI? (1:18)
- What are the implications of these findings for asthma therapy? (3:06)
- What are the remaining unanswered questions regarding the use of this triple therapy? (3:50)
Disclosures: Diego Maselli discloses consulting fees from GSK, AstraZeneca, Sanofi/Regeneron and Amgen.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!